Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2020

Open Access 01-12-2020 | Pancreatic Cancer | Primary research

MAFG-AS1 aggravates the progression of pancreatic cancer by sponging miR-3196 to boost NFIX

Authors: Liqing Ye, Weijian Feng, Hanqin Weng, Chongde Yuan, Jia Liu, Zaiguo Wang

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Abstract

Background

A host of researches have demonstrated the regulation of long non-coding RNAs (lncRNAs) in the progression of pancreatic cancers (PC). In this study, our main task was to analyze the function of MAF bZIP transcription factor G antisense RNA 1 (MAFG-AS1) in PC.

Methods

RT-qPCR measured gene expression. Functional experiments, including EdU assay, flow cytometry analysis, TUNEL assay and transwell assay, assessed the biological changes of PC cells. RNA pull down assay, luciferase reporter assay and RIP assay verified the interaction between RNAs.

Results

MAFG-AS1 was lowly expressed in normal pancreatic samples but up-regulated in PC tissues and cell lines. Besides, MAFG-AS1 silence suppressed cell proliferation and migration whereas promoted cell apoptosis in PC. Mechanism assays verified that miR-3196 could bind with MAFG-AS1. Moreover, miR-3196 was discovered to be lowly expressed in PC cell lines, and its overexpression inhibited PC cell growth and migration. Importantly, nuclear factor I X (NFIX), overexpressed in PC cell lines, was validated to be positively modulated by MAFG-AS1 through absorbing miR-3196. Moreover, overexpression of NFIX could countervail the restraining effects of MAFG-AS1 knockdown on the growth and migration of PC cells.

Conclusion

MAFG-AS1 had an oncogenic function in the progression of PC via regulating miR-3196/NFIX pathway, and decreasing MAFG-AS1 expression could attenuate PC progression.
Appendix
Available only for authorised users
Literature
1.
Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016;22(44):9694–705.CrossRef
2.
Chu LC, Goggins MG, Fishman EK. Diagnosis and detection of pancreatic cancer. Cancer J (Sudbury, Mass). 2017;23(6):333–42.CrossRef
3.
Ren B, Cui M, Yang G, Wang H, Feng M, You L, Zhao Y. Tumor microenvironment participates in metastasis of pancreatic cancer. Mol Cancer. 2018;17(1):108.CrossRef
4.
Shi AW, Shen XF, Ding HJ, Liu YQ, Meng L, Kalionis B. Pancreatic carcinoma underlying a complex presentation in late pregnancy: a case report. J Med Case Rep. 2018;12(1):369.CrossRef
5.
6.
Lei R, Xue M, Zhang L, Lin Z. Long noncoding RNA MALAT1-regulated microRNA 506 modulates ovarian cancer growth by targeting iASPP. OncoTargets Ther. 2017;10:35–46.CrossRef
7.
Lei K, Liang X, Gao Y, Xu B, Xu Y, Li Y, Tao Y, Shi W, Liu J. Lnc-ATB contributes to gastric cancer growth through a MiR-141-3p/TGFbeta2 feedback loop. Biochem Biophys Res Commun. 2017;484(3):514–21.CrossRef
8.
Cui S, Yang X, Zhang L, Zhao Y, Yan W. LncRNA MAFG-AS1 promotes the progression of colorectal cancer by sponging miR-147b and activation of NDUFA4. Biochem Biophys Res Commun. 2018;506(1):251–8.CrossRef
9.
Wang X, Zhou J, Xu M, Yan Y, Huang L, Kuang Y, Liu Y, Li P, Zheng W, Liu H, et al. A 15-lncRNA signature predicts survival and functions as a ceRNA in patients with colorectal cancer. Cancer management and research. 2018;10:5799–806.CrossRef
10.
Lu G, Li Y, Ma Y, Lu J, Chen Y, Jiang Q, Qin Q, Zhao L, Huang Q, Luo Z, et al. Long noncoding RNA LINC00511 contributes to breast cancer tumourigenesis and stemness by inducing the miR-185-3p/E2F1/Nanog axis. J Exp Clin Cancer Res. 2018;37(1):289.CrossRef
11.
Fei D, Zhang X, Liu J, Tan L, Xing J, Zhao D, Zhang Y. Long noncoding RNA FER1L4 suppresses tumorigenesis by regulating the expression of PTEN targeting miR-18a-5p in osteosarcoma. Cell Physiol Biochem. 2018;51(3):1364–75.CrossRef
12.
Liu H, Deng H, Zhao Y, Li C, Liang Y. LncRNA XIST/miR-34a axis modulates the cell proliferation and tumor growth of thyroid cancer through MET-PI3K-AKT signaling. J Exp Clin Cancer Res. 2018;37(1):279.CrossRef
13.
Li H, Yao G, Zhai J, Hu D, Fan Y. LncRNA FTX promotes proliferation and invasion of gastric cancer via miR-144/ZFX axis. OncoTargets Ther. 2019;12:11701–13.CrossRef
14.
Xia P, Liu P, Fu Q, Liu C, Luo Q, Zhang X, Cheng L, Qin T, Zhang H. Long noncoding RNA EPIC1 interacts with YAP1 to regulate the cell cycle and promote the growth of pancreatic cancer cells. Biochem Biophys Res Commun. 2020;522(4):978–85.CrossRef
15.
Liang C, Yang P, Han T, Wang RY, Xing XL, Si AF, Ma QY, Chen Z, Li HY, Zhang B. Long non-coding RNA DILC promotes the progression of gallbladder carcinoma. Gene. 2019;694:102–10.CrossRef
16.
Sui Y, Lin G, Zheng Y, Huang W. LncRNA MAFG-AS1 boosts the proliferation of lung adenocarcinoma cells via regulating miR-744-5p/MAFG axis. Eur J Pharmacol. 2019;859:172465.CrossRef
17.
Li H, Zhang GY, Pan CH, Zhang XY, Su XY. LncRNA MAFG-AS1 promotes the aggressiveness of breast carcinoma through regulating miR-339-5p/MMP15. Eur Rev Med Pharmacol Sci. 2019;23(7):2838–46.PubMed
18.
Ouyang H, Zhang L, Xie Z, Ma S. Long noncoding RNA MAFG-AS1 promotes proliferation, migration and invasion of hepatocellular carcinoma cells through downregulation of miR-6852. Exp Ther Med. 2019;18(4):2547–53.PubMedPubMedCentral
19.
Jia YC, Wang JY, Liu YY, Li B, Guo H, Zang AM. LncRNA MAFG-AS1 facilitates the migration and invasion of NSCLC cell via sponging miR-339-5p from MMP15. Cell Biol Int. 2019;43(4):384–93.CrossRef
20.
Wang T, Tang X, Liu Y. LncRNA-ATB promotes apoptosis of non-small cell lung cancer cells through MiR-200a/beta-Catenin. J BUON. 2019;24(6):2280–6.PubMed
21.
Zhang C, Yang T, Jiang H. miR-511 inhibits proliferation and metastasis of breast cancer cells by targeting FGF4. J Gene Med. 2020;22:e3168.PubMed
22.
Ji ZC, Han SH, Xing YF. Overexpression of miR-3196 suppresses cell proliferation and induces cell apoptosis through targeting ERBB3 in breast cancer. Eur Rev Med Pharmacol Sci . 2018;22(23):8383–90.PubMed
23.
Chen Z, Wu H, Zhang Z, Li G, Liu B. LINC00511 accelerated the process of gastric cancer by targeting miR-625-5p/NFIX axis. Cancer Cell Int. 2019;19:351.CrossRef
Metadata
Title
MAFG-AS1 aggravates the progression of pancreatic cancer by sponging miR-3196 to boost NFIX
Authors
Liqing Ye
Weijian Feng
Hanqin Weng
Chongde Yuan
Jia Liu
Zaiguo Wang
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-01669-y

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue

Primary research

Circular RNA circ_0000284 plays an oncogenic role in the progression of non-small cell lung cancer through the miR-377-3p-mediated PD-L1 promotion

Primary research

Circular RNA circ_0000517 regulates hepatocellular carcinoma development via miR-326/IGF1R axis

Primary research

CAFs affect the proliferation and treatment response of head and neck cancer spheroids during co-culturing in a unique in vitro model

Primary research

circRAE1 promotes colorectal cancer cell migration and invasion by modulating miR-338-3p/TYRO3 axis

Correction

Correction to: Identification of prognosis-related genes and construction of multi-regulatory networks in pancreatic cancer microenvironment by bioinformatics analysis

Primary research

A pooled analysis of the prognostic value of PD-L1 in melanoma: evidence from 1062 patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits